Ajanta Pharma Ltd announces Q1 FY 2027 results and interim dividend approval
Ajanta Pharma · Pharmaceuticals & Biotechnology
Key highlights
- Q1 FY 2027 consolidated revenue up 25% to ₹1,626 crore; PAT up 31% to ₹334 crore
- Board approved 1st interim dividend of ₹32 per share, totaling ₹400 crore, record date 5 August 2026
- Segment growth: India branded generics ₹509 cr (24% growth), US generics ₹487 cr (57% growth), Africa institution ₹70 cr (83% growth)
Why it's rated notable: the year-on-year change is 31% (20% to 50%)
Original filing
Results For 30.06.2026
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Other dividend / buyback / bonus filings this fortnight
- Premco Global Ltd approves Q2 FY 2026-27 results, declares interim dividend, appoints auditor
- Precision Wires India board approves Sept 2026 quarter results and 35% dividend
- Dynamatic Technologies announces Q2 FY27 financial results and interim dividend
- Great Eastern Shipping approves Q2 and H1 results; declares Rs 14.40 interim dividend
- Safari Industries (India) Limited approves Q2 & H1 FY27 results, interim dividend, capex
- IRB Infrastructure Developers announces Q2 & H1 FY27 results and 2nd interim dividend
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.